Analyst Ratings February 24, 2026

KeyBanc Lifts Welltower Price Target to $240, Citing Strength in Private-Pay Senior Housing

Analyst points to demographics, constrained supply and data-driven operations as drivers of above-average earnings growth

By Marcus Reed WELL
KeyBanc Lifts Welltower Price Target to $240, Citing Strength in Private-Pay Senior Housing
WELL

KeyBanc has increased its 12-month price objective for Welltower Inc. (WELL) to $240 from $210 and kept an Overweight rating, signaling confidence in the company's positioning in the private-pay senior housing operating portfolio. The brokerage highlights aging demographics, limited new supply and management's data-focused operating model as catalysts for double-digit internal and per-share earnings growth over the coming years. Recent fourth-quarter results showed revenue upside but an earnings-per-share miss; UBS retained a Buy rating with a $228 target.

Key Points

  • KeyBanc raised its price target on Welltower to $240 from $210 and retained an Overweight rating; the stock at $209.54 implies about 15% upside.
  • The firm cited aging demographics, limited new supply in private-pay senior housing, and management’s data-driven operations as drivers of projected double-digit earnings growth.
  • Welltower beat revenue expectations in 4Q25 with $3.18 billion but missed on EPS ($0.14 vs $0.56); UBS kept a Buy rating with a $228 target and noted $13.9 billion in quarter investments.

KeyBanc has adjusted its valuation outlook for Welltower Inc., raising its price target to $240.00 from $210.00 while maintaining an Overweight rating on the shares. With the stock trading at $209.54, KeyBanc's new target implies roughly 15% upside to its projection.

The firm points to Welltower's exposure to secular demand within the private-pay senior housing operating portfolio segment as the principal rationale behind the higher target. KeyBanc analyst Austin Wurschmidt emphasized demographic and supply-side dynamics - specifically an aging population profile paired with limited new supply - as underpinning assumptions for the firm's optimistic view.

Wurschmidt additionally identified management's emphasis on data-driven decision making across operations and capital allocation as a source of potential value creation. According to KeyBanc, those factors leave Welltower well placed to achieve double-digit internal and per-share earnings growth in the years ahead.

"Following Its North Star with Another Year of DoubleDigit Earnings Growth; We continue to view WELL’s platform and execution as among the best positioned to capitalize on secular demand trends within the private pay SHOP segment."

KeyBanc also revised its 2026 and 2027 estimates higher in the wake of Welltower's fourth-quarter results, and said the new price target reflects the company's demonstrated capacity to attain above-average earnings gains.

Performance metrics over the trailing year show the company has delivered a total return of 41.5%. At the same time, a valuation analysis available on a research platform indicates the shares are trading above that platform's Fair Value estimate. That same research product, the firm notes, provides additional valuation detail and 15 supplementary ProTips in its comprehensive report.

Welltower's fourth-quarter 2025 results contained mixed signals. The company reported revenue of $3.18 billion, exceeding consensus forecast of $2.85 billion - an 11.58% positive surprise. However, reported earnings per share were $0.14, below the expected $0.56.

Following the quarter, UBS maintained a Buy rating on Welltower and left its price target at $228.00. UBS's review of the quarter highlighted substantial investment activity, with Welltower reporting $13.9 billion in fourth-quarter investments. That level of investment surpassed UBS's own estimate of $10.5 billion and the consensus expectation of $9.2 billion.

The company also reported robust same-store net operating income growth of 15.0% across its total portfolio, and management provided guidance the research community described as strong for 2026. KeyBanc's estimate upgrades for 2026 and 2027 followed directly from the quarter's reported results and management commentary.

Investors evaluating Welltower will weigh the firm's growth profile in the private-pay senior housing segment, management's operational approach and recent financial results - including the revenue beat and EPS shortfall - as they assess the company's trajectory and valuation relative to peers.


Key points

  • KeyBanc raised its price target on Welltower to $240 from $210 and maintained an Overweight rating, implying about 15% upside from the current share price of $209.54.
  • The brokerage cited aging demographics, constrained new supply in the private-pay senior housing sector, and a management team focused on data-driven operations as primary growth drivers.
  • Welltower reported $3.18 billion in fourth-quarter revenue, surpassing the $2.85 billion forecast, while EPS of $0.14 missed expectations of $0.56; UBS maintained a Buy rating with a $228 target after the quarter.

Risks and uncertainties

  • Near-term earnings volatility - the company delivered a material revenue beat but an EPS miss in the fourth quarter, which introduces uncertainty for short-term earnings trends. This impacts investors in the REIT and healthcare real estate sectors.
  • Valuation concerns - a research platform's analysis indicates the shares are currently trading above its Fair Value estimate, suggesting upside may be constrained if market sentiment shifts. This risk affects equity investors and portfolio managers focused on REIT allocations.
  • Execution and investment cadence - while the company reported substantial investment volumes in the quarter, actual returns on those investments and continued execution will influence future guidance and sector sentiment, particularly within senior housing and healthcare property markets.

Risks

  • Short-term earnings uncertainty, evidenced by a revenue beat accompanied by an EPS shortfall, which may affect near-term investor confidence in REIT and healthcare real estate sectors.
  • Valuation risk, as a research platform’s analysis shows the stock trading above its Fair Value estimate, posing downside if market re-rates the shares.
  • Execution risk tied to the large level of reported investments; returns on those investments will determine whether elevated capital deployment translates into sustained earnings growth for senior housing and healthcare property markets.

More from Analyst Ratings

Freedom Capital nudges up MDU Resources target as utility businesses drive gains Feb 24, 2026 BofA Maintains Buy on Eli Lilly, Sees Little U.S. GLP-1 Impact from Novo Price Move Feb 24, 2026 Benchmark Lifts SGHC Price Target After Fiscal 2025 Beat; Buy Rating Reiterated Feb 24, 2026 Benchmark Lifts Zoom Price Target to $115, Cites AI Strategy and Strong Fundamentals Feb 24, 2026 Benchmark Upholds Buy Rating on Diamondback After Mixed Q4 Results Feb 24, 2026